EHRA Premium Access

Intravenous antazoline for cardioversion of recent onset atrial fibrillation in patients with stable coronary artery disease.

Congress Presentation

About the speaker

Doctor Michal Farkowski

National Institute of Cardiology, Warsaw (Poland)
0 follower

6 more presentations in this session

Vernakalant versus ibutilide for immediate conversion of recent-onset Atrial Fibrillation

Speaker: Doctor I. Vogiatzis (Veria, GR)

Thumbnail

Impact of gender: rivaroxaban for patients with atrial fibrillation in the XANTUS real-world prospective study

Thumbnail

Comparison of local activation time annotation algorithms in high density mapping of regular atrial tachycardias

Speaker: Professor J. De Pooter (Gent, BE)

Thumbnail

Higher persistence but lower compliance with direct oral anticoagulants treatment for atrial fibrillation following a personalized therapeutic information: paradoxical results of the MONACO study

Speaker: Professor J. Davy (Montpellier, FR)

Thumbnail

A real-world comparison of vernakalant efficacy and safety for pharmacological cardioversion in patients with recent-onset atrial fibrillation in an emergency department and after cardiac surgery.

Speaker: Doctor J. Osca Asensi (Valencia, ES)

Thumbnail

Access the full session

Poster session 1 - Atrial Fibrillation - Antiarrhythmic drugs

Speakers: Doctor M. Farkowski, Doctor I. Vogiatzis, Professor J. De Pooter, Professor J. Davy, Doctor J. Osca Asensi
Thumbnail

About the event

Image

EHRA EUROPACE - CARDIOSTIM 2017

18 June - 21 June 2017

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb